AOD-9604: The Fat-Loss Peptide — Does It Really Work?

What AOD-9604 actually is

AOD-9604, sometimes written as "GH fragment 176-191," is a synthetic peptide that reproduces the last sixteen amino acids of human growth hormone, specifically residues 176 through 191 of the C-terminus. It was engineered in the 1990s at Monash University in Australia by a research group led by Frank Ng, with a very specific hypothesis: that the fat-mobilizing actions of growth hormone could be isolated from its other metabolic effects if you stripped the molecule down to the relevant fragment.

The appeal is mechanistic. Full-length growth hormone is a powerful but messy drug. It mobilizes fat, but it also raises insulin-like growth factor 1 (IGF-1), worsens insulin resistance, can drive fluid retention and carpal tunnel symptoms, and is implicated in tissue overgrowth at supraphysiologic doses. AOD-9604 was designed to keep the lipolytic signal and discard the rest.

At Regeneris Therapy, we treat AOD-9604 the way we treat any peptide in this category: as an investigational tool with a coherent mechanism and a clinical evidence base that is, frankly, less impressive than the marketing.

Proposed mechanism: lipolysis without the GH baggage

In preclinical work and early human pharmacology studies, AOD-9604 appears to stimulate lipolysis (the breakdown of stored triglycerides in adipose tissue) and inhibit lipogenesis (the formation of new fat) without producing the glucose-handling problems associated with full-length growth hormone. In animal models of obesity it produced reductions in body fat at doses that did not elevate IGF-1, did not raise fasting glucose, and did not cause the soft-tissue overgrowth typical of GH excess.

That separation, if it holds up in humans at clinically meaningful doses, would be genuinely useful. It is also the part of the AOD-9604 story that has been most aggressively oversold in the consumer peptide market.

What the clinical evidence actually shows

This is where honesty matters. AOD-9604 advanced through Phase 2 clinical trials in humans for obesity, sponsored by Metabolic Pharmaceuticals in Australia in the mid-2000s. A pivotal twelve-week, randomized, placebo-controlled Phase 2b trial enrolled more than five hundred obese adults across multiple AOD-9604 doses. The result, published in the medical literature, was that AOD-9604 failed to meet its primary endpoint for weight loss versus placebo at the doses tested. The safety profile was reassuring, no IGF-1 elevations, no glucose problems, no notable adverse signal, but the efficacy was simply not there at a magnitude that would support an obesity indication.

Subsequent development for obesity was discontinued. The molecule was later marketed in some jurisdictions as a dietary ingredient and pursued for other indications, including osteoarthritis, where the rationale shifts toward cartilage and chondrocyte effects rather than fat loss. In 2026, AOD-9604 remains an investigational peptide with no major regulatory approval as a fat-loss therapy in the United States, the European Union, or Mexico.

What this means for the honest clinician is straightforward. The mechanism is plausible. The safety signal in trials was clean. The efficacy signal, in the one well-powered trial that asked the right question, was negative. Anyone promising dramatic fat loss from AOD-9604 alone is overstating what the human data support.

AOD-9604 versus Tesamorelin

Patients often ask how AOD-9604 compares to Tesamorelin, a growth-hormone-releasing hormone analog approved by the FDA for HIV-associated lipodystrophy and frequently used off-label for visceral fat reduction. The comparison is instructive because the two molecules sit on opposite sides of the GH axis.

Tesamorelin works upstream: it stimulates the pituitary to release the patient's own growth hormone in a pulsatile, more physiologic pattern. Its clinical trials in lipodystrophy showed statistically and clinically meaningful reductions in visceral adipose tissue, with measurable IGF-1 elevations as part of the mechanism. It has a regulatory approval, a defined indication, and a real evidence base.

AOD-9604 works downstream of the GH receptor, bypassing pituitary signaling entirely and acting as a direct lipolytic peptide at adipose tissue, in theory. It has no equivalent regulatory approval and no large positive trial to anchor its use.

For a patient whose clinical question is "how do I reduce visceral fat under medical supervision," the honest answer in 2026 is that Tesamorelin has stronger evidence, particularly in metabolic and HIV-associated visceral adiposity. AOD-9604 may have a role as an adjunct in a broader, supervised protocol, but it should not be presented as a primary fat-loss therapy.

Typical dosing and contraindications

Where AOD-9604 is prescribed off-label as part of a supervised regenerative or metabolic protocol, dosing in the published pharmacology and clinical literature has typically ranged from 300 micrograms to 1 milligram daily, administered subcutaneously, usually in the morning on an empty stomach to align with endogenous fasting lipolysis. Cycles in clinical practice tend to run twelve weeks with structured reassessment.

Contraindications and caution categories include active malignancy, pregnancy and breastfeeding, pediatric use, uncontrolled diabetes, and patients on medications or peptides with overlapping mechanisms where stacking has not been evaluated. A responsible prescriber will screen for all of these in advance, baseline an IGF-1 and fasting glucose panel, and re-test on a defined schedule even though AOD-9604 in trials did not move those markers.

The boring point that matters: no peptide outperforms a sustained caloric deficit, resistance training, sleep, and protein intake. AOD-9604 is not a substitute for any of those, and any clinic presenting it that way is selling, not treating.

COFEPRIS regulation and the Mexican context

In Mexico, the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) regulates pharmaceutical substances and the clinical settings in which they are administered. As of 2026, AOD-9604 is not a COFEPRIS-registered finished pharmaceutical product with an approved indication for fat loss or any other condition. Where it is used clinically, it is accessed through regulated compounding pharmacies operating under *farmacia magistral* frameworks, with documented sourcing, identity testing, and chain of custody.

For a patient considering AOD-9604 in Cancún or elsewhere in Mexico, three practical points apply:

• Prescription is required. AOD-9604 should be dispensed only with a written prescription from a licensed Mexican physician after an in-person evaluation. Direct-to-consumer online sales labeled as "research chemicals" sit outside the standard of care.
• Source and purity are not optional. Compounded peptides should come from pharmacies that provide Certificates of Analysis documenting identity, purity, and absence of endotoxin. A reputable clinic will show you these documents for your specific lot.
• The clinical setting matters. Administration should occur within a COFEPRIS-notified clinical environment, with informed consent that acknowledges the investigational nature of the therapy and the negative Phase 2b primary endpoint.

This is the regulatory and ethical posture we maintain at Regeneris Therapy.

Who is a reasonable candidate

There is no universal candidate for AOD-9604, and given the negative pivotal trial it should never be positioned as a primary fat-loss intervention. Where it is sometimes considered, within a supervised plan, is in selected adults pursuing a comprehensive metabolic and regenerative protocol where AOD-9604 may serve as one minor lever among several, and where the patient understands the limits of the evidence.

It is not a reasonable choice for patients seeking a shortcut around lifestyle intervention, for anyone with a contraindication, or for anyone who has been told by a clinic that it will produce significant weight loss on its own. The honest framing is that AOD-9604 is an investigational adjunct with a clean safety profile and a disappointing efficacy record at the only endpoint that was rigorously tested.

Moving forward with clarity

AOD-9604 sits in a specific place on the evidence curve: a mechanistically interesting peptide whose pivotal human trial did not deliver on the fat-loss promise. That does not make it useless, but it does make any "miracle peptide" marketing dishonest. Used within a broader, physician-led plan, sourced from a reputable compounding pharmacy, and paired with the unglamorous fundamentals of nutrition, training, and sleep, it can be one small part of a serious protocol. Used as a standalone fat-loss product bought online, it is, at best, an expensive disappointment.

If you are weighing peptide therapy in Cancún as part of a broader anti-aging and longevity plan, the right first step is a physician evaluation, not a product order. You can learn more about our physicians on the team page and reach the Regeneris Therapy medical team directly to schedule a consultation.

Related reading

• BPC-157 in Mexico: What We Know as of 2026
• A Beginner's Guide to Peptide Therapy